long intergenic non-protein coding RNA 1793Genealiases: []
Q-omics provides the consensus-scored LINC01793 profile across patient tissues and cancer cell-line models. LINC01793 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LINC01793 is differentially expressed in 2, with the highest sampling consensus in LIHC. Additionally, LINC01793 RNA expression shows 8,618 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, LIHC, and TGCT as cancer lineages where LINC01793 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01793 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01793 survival associations across molecular data types. LINC01793 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01793 RNA expression–survival associations across cancer types. High LINC01793 expression shows unfavorable associations in KIRC, KICH, ACC, CESC, STAD and CHOL. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for LINC01793 RNA expression.
This table summarizes LINC01793 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01793. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01793 shows lower tumor expression in THCA and higher tumor expression in LIHC. The LIHC box plot shows higher LINC01793 RNA expression in tumor versus normal tissue (log2 FC = +0.136, t-test p = .010).
This table shows molecular features associated with LINC01793 in patient tissues and cancer cell lines. In patient samples, LINC01793 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
